Key result
Low-molecular-weight heparin is at least as effective as unfractionated heparin for the treatment of pulmonary embolism, with a similar risk of bleeding and more predictable pharmacokinetics.
Why the study?
Is low-molecular-weight heparin as effective and safe as unfractionated heparin for the inpatient and outpatient treatment of pulmonary embolism?
Is low-molecular-weight heparin as effective and safe as unfractionated heparin for the inpatient and outpatient treatment of pulmonary embolism?
Low-molecular-weight heparin is recommended over unfractionated heparin for submassive pulmonary embolism due to comparable efficacy, similar bleeding risk, and the potential for feasible outpatient management.
Answers are grounded in this paper and cite their sources.
May support LMWH preference for PE; leaves open need for contemporary RCTs on outpatient outcomes.
Pulmonary embolism (PE) remains a major clinical problem associated with considerable mortality and morbidity. In patients with PE, appropriate anticoagulant therapy has been shown to significantly reduce both recurrence and mortality. Low-molecular-weight heparin (LMWH) is at least as effective as unfractionated heparin (UFH) in the treatment of PE, with a similar risk of bleeding. Furthermore, LMWH offers more predictable pharmacokinetics and anticoagulant effects. As a result, current guidelines from both the American College of Chest Physicians and the joint American College of Physicians/American Academy of Family Physicians recommend the use of LMWH over UFH (in patients with submassive PE). Outpatient treatment with LMWH has been shown to be feasible in many patients, and offers the potential for cost-savings and improvements in health-related quality of life. Further data are needed to support an evidence-based recommendation for the use of LMWH in the outpatient treatment of PE.
No takes yet. Share an insight, caveat, or question.
Russell D. Hull (2008) conducted a review in Pulmonary embolism. Low-molecular-weight heparin (LMWH) vs. Unfractionated heparin (UFH) was evaluated. Low-molecular-weight heparin is at least as effective as unfractionated heparin for the treatment of pulmonary embolism, with a similar risk of bleeding and more predictable pharmacokinetics.
Synapse has enriched 10 related papers. Consider them for comparative context: